GlassScriptPhysician profile
Hannah Braun
NPI 1427352426
$3,318.42
in general payments reported to CMS, 2019-2025
24 companies · $968 in 2025
The $968 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $382 · 2022: $563 · 2023: $494 · 2024: $911 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $578.14 | 2022-2024 | Jornay Pm |
| Corium, LLC | $479.26 | 2022-2025 | Azstarys, Azstarys |
| Neurelis, INC. | $339.13 | 2022-2025 | Valtoco |
| Pfizer INC. | $279.52 | 2021-2025 | |
| Tris Pharma INC | $182.87 | 2021-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $179.03 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi-Aventis U.S. LLC | $162.95 | 2025 | |
| Seqirus USA INC | $137.55 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Glaxosmithkline, LLC. | $135.76 | 2021-2025 | Bexsero, Rotarix, Penmenvy |
| Neos Therapeutics, LP | $135.64 | 2021-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Supernus Pharmaceuticals, INC. | $130.25 | 2023-2025 | Qelbree, Qelbree |
| Adlon Therapeutics L.P. | $112.87 | 2021 | |
| Collegium Pharmaceutical, INC. | $81.38 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $54.65 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $53.48 | 2021-2024 | Crysvita |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $49.07 | 2023-2025 | Doc Band |
| Kaleo, INC. | $45.97 | 2022-2023 | Auvi-Q |
| Sobi, INC | $42.09 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $32.66 | 2022 | |
| Sanofi Pasteur INC. | $30.63 | 2021-2022 | |
| Modernatx, INC. | $24.68 | 2023 | Moderna Covid-19 Vaccine |
| Ars Pharmaceuticals Operations, INC. | $18.85 | 2025 | Neffy |
| Verrica Pharmaceuticals INC. | $18.27 | 2025 | Ycanth |
| Vertical Pharmaceuticals, LLC | $13.72 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Braun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.